TASK
Welcome,         Profile    Billing    Logout  
 2 Trials 
6 Trials

   

 
Trial + Data / EventsStatusPhNRegionInterventionsSponsorConditionsPrimary complStudy compl
Diacon, Andreas
Sisonke Boost, NCT05148845: Sisonke 2 - A COVID-19 Vaccine Boost Open Label Study.

Recruiting
3b
500000
RoW
Booster vaccine
Wits Health Consortium (Pty) Ltd, National Department of Health of South Africa, National Institute of Communicable Diseases - NICD, KwaZulu-Natal Research Innovation and Sequencing Platform - KRISP, Fred Hutchinson Cancer Center, Hutchinson Center Research Institute of South Africa (HCRISA), Janssen Vaccines & Prevention B.V., Bio Analytical Research Corporation, Dis-Chem Pharmacy, BioVac, Biocair, Right to Care, Clinical Laboratory Services, Institute of Infectious Disease and Molecular Medicine
SARS CoV 2 Infection
01/22
06/23
NCT05896930: Study to Evaluate EBA, Safety and Tolerability of Carbapenems in Adults With Pulmonary Tuberculosis

Completed
2
134
RoW
Meropenem 6g IV over 6 hours, Ertapenem 1g IM, Meropenem 3g IV, Ertapenem 1g IV, Amoxicillin/CA twice daily, Rifampicin 35 mg/kg, Meropenem 6g IV over 60 minutes, Rifafour e-275, Meropenem 4g IV, Amoxicillin/CA once daily
TASK Applied Science
Pulmonary Tuberculosis
01/21
01/21
NCT04621825: Post Market Surveillance Study to Confirm Safety and Performance of Silicone PHMB Foam

Completed
N/A
187
RoW
ActivHeal Silicone PHMB Foam Adhesive and Non Adhesive dressing.
Advanced Medical Solutions Ltd., Imarc Research, Inc.
Wound
05/24
07/24
Ryklief, Fairoez
DECISION, NCT05926466: BTZ-043 Dose Evaluation in Combination and Selection

Recruiting
2
90
RoW
BTZ-043, Bedaquiline, SIRTURO®, Delamanid, OPC-67683, Deltyba, Moxifloxacin, Lonxave
Michael Hoelscher, Radboud University Medical Center, University of California, San Francisco, University College, London
Tuberculosis, Pulmonary, Other Specified Pulmonary Tuberculosis
08/24
08/24
NCT05807399: PanACEA - STEP2C -01

Recruiting
2
270
RoW
BTZ-043, Rifampicin, Isoniazid, Pyrazinamide, Moxifloxacin
Michael Hoelscher, Radboud University Medical Center, University of California, San Francisco, University College, London
Pulmonary Tuberculosis, Other Specified Pulmonary Tuberculosis
02/25
02/25
PARADIGM4TB, NCT06114628: Platform Assessing Regimens and Durations In a Global Multisite Consortium for TB

Recruiting
2
2500
RoW
GSK3036656, BTZ-043, Bedaquiline (B), Delamanid (D), Pretomanid (Pa), Moxifloxacin (M), Linezolid (L), Pyrazinamide (Z), Rifampicin (R), Isoniazid (H), Ethambutol (E)
University College, London, Radboud University Medical Center, London School of Hygiene and Tropical Medicine, University of Oxford, Research Center Borstel, Lygature, TASK Applied Science, Vita-Salute San Raffaele University, Helmholtz Zentrum Munchen, KNCV Tuberculosis Foundation, Critical Path Institute, European Lung Foundation, Instituto de Saude Publica da Universidade do Porto, University of Liverpool, Institut de Recherche Pour le Developpment, University of Hamburg-Eppendorf, University of California, San Francisco, TB Alliance, Find, University of Milano, University of St Andrews, Uppsala University, European Respiratory Society, Tuberculosis Network European Trialsgroup, Janssen, LP, Otsuka Pharmaceutical Development & Commercialization, Inc., German Center for Infection Research, LMU University Hospital Munich, University of Cambridge, GlaxoSmithKline
Pulmonary Tuberculosis
02/27
08/27

Download Options